<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005262</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 16-0122</org_study_id>
    <nct_id>NCT03005262</nct_id>
  </id_info>
  <brief_title>MLN8237 for a Subject With Adenocarcinoma of the Prostate</brief_title>
  <official_title>Expanded Access To MLN8237, For An Individual Patient With Adenocarcinoma Of The Prostate (CTMS# 16-0122)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <brief_summary>
    <textblock>
      To allow a patient continued access to MLN8237
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expanded access to MLN8237 for an individual patient with adenocarcinoma of the prostate
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN8237</intervention_name>
    <other_name>Alisertib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Histologically or cytologically confirmed advanced tumors and candidates for docetaxel
             treatment

          -  Measurable or evaluable disease is required. Patients must have clinical evidence of
             progressive disease or persistent disease

          -  Patients with castration-resistant prostate cancer (CRPC) are required to have

          -  Pathologically confirmed adenocarcinoma of the prostate

          -  Evidence of metastatic disease on bone scan or other imaging. Patients with PSA
             elevation as the only manifestation of disease are not eligible.

          -  Progressive disease after at least 1 hormonal treatment with documented testosterone
             levels less than 50 ng/dl

          -  Concurrent use of an agent for testosterone suppression (e.g., LHRH agonist) is
             required if the patient has not been surgically castrated

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Recovered to less than or equal to Grade 1 toxicity (CTCAE), to patient's baseline
             status (except alopecia) or deemed irreversible from the effects of prior cancer
             therapy and must have evidence of progressive or persistent disease

          -  Adequate bone marrow, liver and renal function

          -  Any use of opiates must be stable for at least 2 weeks prior to study entry

          -  Male patients who agree to practice effective barrier contraception during the entire
             study and through 6 months after the last dose of study drug OR agree to abstain from
             heterosexual intercourse

          -  Voluntary written consent

          -  Willing to comply with scheduled visits, treatment plan, laboratory tests and other
             trial procedures

          -  Suitable venous access for blood sampling

        Exclusion Criteria:

          -  Antineoplastic therapy or any experimental therapy within 21 days before the first
             dose of MLN8237

          -  Prior or current investigational therapies within 4 weeks before the first dose of
             MLN8237

          -  Radiotherapy to greater than 40% of bone marrow or any radiotherapy (except localized,
             small field radiation) within 4 weeks prior to enrollment, unless reviewed and
             approved by the medical monitor

          -  Nitrosoureas or mitomycin-C within 6 weeks before the first dose of MLN8237.

          -  Autologous stem cell transplant within 3 months before the first dose of MLN8237, or
             prior allogeneic stem cell transplant at any time.

          -  Use of enzyme-inducing antiepileptic drugs such as phenytoin, carbamazepine or
             phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days
             prior to the first dose of MLN8237

          -  For CRPC patients:

          -  Radiotherapy or antiandrogen therapy for prostate cancer within 4 weeks prior to
             enrollment

          -  Prior treatment with antineoplastic chemotherapy or radioisotopes for advanced
             prostate cancer

          -  Use of products known to affect PSA levels within 4 weeks of enrollment

          -  Major surgery within 4 weeks of study enrollment

          -  Uncontrolled high blood pressure

          -  Patients with abnormal gastric or bowel function or who require continuous treatment
             with antacids or proton pump inhibitors

          -  Patients receiving chronic steroid therapy other than the following: low dose steroid
             for the control of nausea and vomiting, topical steroid, inhaled steroid or use of
             dexamethasone

          -  Known severe hypersensitivity to docetaxel or other drugs formulated in polysorbate 80

          -  Comorbid condition or unresolved toxicity that would preclude administration of
             docetaxel

          -  Prior history of Grade 2 or greater neurotoxicity or any toxicity that has not
             resolved to Grade 1 or below

          -  Symptomatic brain or other CNS metastasis

          -  Diagnosis or treatment of another malignancy within 2 years preceding first dose of
             study drug except nonmelanoma skin cancer or in situ malignancy completely resected

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  Patients requiring full systemic anticoagulation

          -  Prior allogeneic bone marrow or other organ transplant

          -  Active infection requiring systemic therapy within 14 days preceding first dose, or
             other serious infection

          -  History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months

          -  Serious medical or psychiatric illness that could interfere with protocol completion

          -  Inability to swallow oral medication

          -  Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens

          -  Prior treatment with more than 1 prior taxane-containing regimen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

